Methods for Treating Inflammatory Autoimmune Disorders (BIDMC 1236)

Beth Israel Deaconess Medical Center
posted on 01/12/2012

The invention features the treatment of gastrointestinal disorders associated with an innate immune response triggered by alpha amylase inhibitor CM3, alpha amylase inhibitor 0.19 (0.19), CMl, CM2, CMa, CMd, CM 16, CMb, CMX1/CMX3, CMX2, and/or alpha amylase inhibitor 0.53 (0.53). To this end, the invention features pharmaceutical compositions including neutralizing antibodies to CM3, 0.19, CMl, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53, food products containing reduced levels of CM3, 0.19, CMl, CM2, CMa, CMd, CMl 6, CMb, CMX1/CMX3, CMX2, and/or 0.53 protein, the use of oral TLR4 inhibitors to block the effect of said alpha-amylase inhibitors, assays for identifying CM3, 0.19, CMl, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 content in food products, and assays for diagnosing subjects with a disorder related to CM3, 0.19, CMl, CM2, CMa, CMd, CM 16, CMb, CMX1/CMX3, CMX2, and/or 0.53 triggered innate immune responses.

Innovation Details

File Number: 806

Web site: https://research.bidmc.harvard.edu/TVO/tvotech....

Other Information:

Investigator(s)
Dr. George Tsokos

Contact
Stanley, Mah C

IP Protection

License Online

This innovation currently is not available for online licensing. Please contact Abi Barrow at Beth Israel Deaconess Medical Center for more information.

request more info